• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Karuna Therapeutics Is Doing Important Research but Its Charts Are Weak

The technical signals of the clinical-stage biotech company don't inspire confidence at this juncture.
By BRUCE KAMICH
Dec 02, 2021 | 09:03 AM EST
Stocks quotes in this article: KRTX

In his second Executive Decision segment of "Mad Money" Wednesday, host Jim Cramer spoke with Dr. Steve Paul, chairman, president and CEO of Karuna Therapeutics  (KRTX) , a clinical-stage biotech working to develop treatments for patients with schizophrenia and other psychotic disorders.

Paul said many treatments for schizophrenia and Alzheimer's disease today are similar to ones developed 70 years ago. That's why Karuna is so excited about its therapies, which have shown promising results without the significant side effects of those older therapies, Paul said.

Let's check out the charts of KRTX.

In this daily bar chart of KRTX, below, we can see that prices have made an irregular uptrend the past 12 months. Prices have rallied but corrections have been lengthy affairs. Prices are currently trading below the 50-day moving average line and just a fraction above the 200-day line. The On-Balance-Volume (OBV) line declined from February to August and then made a temporary recovery to early November. This pattern does not inspire confidence. The Moving Average Convergence Divergence (MACD) turned lower last month and is now crossing below the zero line for a sell signal.

In this weekly Japanese candlestick chart of KRTX, below, we can see a weakening picture. Prices have risen from late 2019 but they are testing the rising 40-week moving average line too much. It is bullish to see a test of the 40-week line and then a rally, but prices here are hugging the line or have traded below it too much for my liking. The OBV line has drifted lower the past two years, so this is another problem for chart watchers. The MACD oscillator has been weak for the past two years, telling us that KRTX has not had a strong trend.

In this daily Point and Figure chart of KRTX, below, we can see a potential downside price target in the $99 area.

Bottom line strategy: For personal reasons I truly hope that Karuna Therapeutics does find a new and better way to treat schizophrenia, but unfortunately I cannot recommend purchase of its stock at this point in time. Avoid.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Biotechnology | Healthcare | Life Sciences | Pharmaceuticals | Mad Money | Executive Interview | Real Money

More from Stocks

Warning: Watch for Bull Trap

James "Rev Shark" DePorre
Jun 30, 2022 4:32 PM EDT

After an ugly day of bear market trading, beware of what could hide ahead on Friday.

For This REIT It's All About That Base

Bruce Kamich
Jun 30, 2022 4:10 PM EDT

We're checking the charts and indicators on Ventas, owner of senior housing and medical facilities.

This ETF Boasts 'Inflation Protection,' but Will It Rise to the Occasion?

Mark Abssy
Jun 30, 2022 3:26 PM EDT

The Ionic Inflation Protection exchange-traded fund, the latest such ETF to hit the market, offers direct exposure to the consumer price index.

Want to Save Your Retirement Fund? Tune Out the Talking Heads

Jim Collins
Jun 30, 2022 3:14 PM EDT

The first half of this year has been ugly. But we could have seen what would happen to Netflix, Tesla and Meta...

National Health Investors Is Aging Well as It Emerges From a Base Formation

Bruce Kamich
Jun 30, 2022 2:16 PM EDT

Buyers of the shares are becoming more aggressive.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:59 PM EDT PAUL PRICE

    Very good quarterly numbers from Bassett Furniture (BSET)

    Bassett Furniture (BSET) blew right through analys...
  • 04:41 PM EDT PAUL PRICE

    First Half Results - Putrid Second Half Results - Likely to Be Much Better

    It's great that we're done with June. 2022 marked...
  • 04:51 PM EDT PAUL PRICE

    We Should Be in for Better Starting Soon

    Window dressing Thursday, the last day of the...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login